Merck & Co Inc

NYSE: MRK
$98.36
-$0.14 (-0.1%)
Closing Price on November 14, 2024

MRK Articles

After an absence of more than a year, Apple is once more the top-performing Dow stock for the year to date. Considering the company's market cap of $1.05 trillion, that's quite an accomplishment.
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Merck reported better-than-expected second-quarter results before the markets opened on Friday, but shares retreated afterward.
The July 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
24/7 Wall St. has put together a preview of Boeing, Exxon, Verizon and other Dow industrials scheduled to report their quarterly results this week.
Four pharmaceutical industry leaders are poised to report second-quarter results next week, and one key analyst sees the relatively good print from Johnson & Johnson as a good signal for the...
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Intel, Walgreens, Johnson & Johnson, and Merck led the Dow higher Thursday.
Merck shares retreated to start off the week despite the announcement of good news from the FDA.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The fear of a massive global trade war is one that has just not been part of the investing lexicon in years. So what are confused investors to do now?
Intel, P&G, Travelers, and Merck were Monday's worst performing Dow stocks.
General Electric, JPMorgan, Merck, and Coca-Cola weighed on the Dow Thursday.
Merck & Co., Inc. (NYSE: MRK) shares took a small step back on Thursday after the company announced a key approval from the U.S. Food and Drug Administration. The agency has now approved Keytruda...